Herceptin is new option in advanced HER2-positive gastric cancer, say experts
This article was originally published in Scrip
Executive Summary
Roche's (Genentech) HER2-targeted breast cancer drug Herceptin (trastuzumab) was recommended by experts as a new option in HER2-positive advanced gastric cancer after it prolonged median overall survival by almost three months when added to chemotherapy in the pivotal first-line ToGA trial, the results of which were presented at the ASCO meeting in Orlando this week.